WO2009140215A3 - Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds - Google Patents
Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds Download PDFInfo
- Publication number
- WO2009140215A3 WO2009140215A3 PCT/US2009/043505 US2009043505W WO2009140215A3 WO 2009140215 A3 WO2009140215 A3 WO 2009140215A3 US 2009043505 W US2009043505 W US 2009043505W WO 2009140215 A3 WO2009140215 A3 WO 2009140215A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- resistant
- compounds
- bacteria
- strains
- phanquinone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to new uses of known chelating compounds for the treatment of bacterial in fungal infections, particularly by methicilllin-resistant and other drug-resistant strains of bacteria and fungi. One of more chelating compound is administered with or without additional antibiotic or antifungal drugs to achieve improved therapy. Preferred chelating compounds include clioquinol, 5,7-dichloro-8-hydroxy-quinaldine, phanquinone, 5,7-dichloro-8-hydroxyquinoline, 5,7- di-iodo-8-hydroxyquinoline. By chelation of specific metal ions, these compounds treat any infection by bacteria or fungi whose pathogenicity depends upon metalloenzymes that require these cations. The compounds are also effective against infections caused by extended β lactamase and metallo β lactamase producing bacterial strains. Bacteria targeted by these methods include methicillin-resistant Staphylococcus aureus, penicillin resistant or intermediate resistant Streptococcus pneumoniae and other gram positive and multiresistant gram negative species and strains.
Applications Claiming Priority (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5221208P | 2008-05-11 | 2008-05-11 | |
US61/052,212 | 2008-05-11 | ||
US5304008P | 2008-05-14 | 2008-05-14 | |
US61/053,040 | 2008-05-14 | ||
US5603208P | 2008-05-26 | 2008-05-26 | |
US61/056,032 | 2008-05-26 | ||
US5607708P | 2008-05-27 | 2008-05-27 | |
US61/056,077 | 2008-05-27 | ||
US5711708P | 2008-05-29 | 2008-05-29 | |
US61/057,117 | 2008-05-29 | ||
US7877108P | 2008-07-08 | 2008-07-08 | |
US61/078,771 | 2008-07-08 | ||
US15691109P | 2009-03-03 | 2009-03-03 | |
US61/156,911 | 2009-03-03 | ||
US15946309P | 2009-03-12 | 2009-03-12 | |
US61/159,463 | 2009-03-12 | ||
US16894409P | 2009-04-14 | 2009-04-14 | |
US61/168,944 | 2009-04-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009140215A2 WO2009140215A2 (en) | 2009-11-19 |
WO2009140215A3 true WO2009140215A3 (en) | 2010-03-11 |
Family
ID=41319274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/043505 WO2009140215A2 (en) | 2008-05-11 | 2009-05-11 | Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009140215A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107847507A (en) * | 2015-05-29 | 2018-03-27 | 德克抗生素股份公司 | For treating the halo salicylanilide of fusobacterium infection |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2940289B1 (en) * | 2008-12-23 | 2014-09-12 | Biopharmed | AMINO HYDROXYQUINOLINE CLASS DERIVATIVES FOR THE TREATMENT OF PANCREATIC CANCER |
GB0900786D0 (en) * | 2009-01-19 | 2009-03-04 | Natracine Uk Ltd | Therapeutic compositions |
CN104945420A (en) | 2009-06-29 | 2015-09-30 | 因塞特公司 | Pyrimidinones as PI3K inhibitors |
IN2012DN01449A (en) | 2009-07-17 | 2015-06-05 | Univ Denmark Tech Dtu | |
WO2011017519A2 (en) * | 2009-08-05 | 2011-02-10 | The Johns Hopkins University | Inhibitors of methionine aminopeptidases and methods of treating disorders |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
EP2345643A1 (en) * | 2009-12-29 | 2011-07-20 | Polichem S.A. | New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof |
CN101797251A (en) * | 2010-01-21 | 2010-08-11 | 复旦大学 | Inhibitor for acetylcoenzyme A synthetase in human pathogen clostridium difficile |
JP5816678B2 (en) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションIncyte Corporation | Condensed derivatives as PI3Kδ inhibitors |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
EP2637679A4 (en) * | 2010-11-09 | 2015-09-23 | Univ Chicago | Role of adam10 and its relevance to disease and therapeutics |
BR112013014735A2 (en) | 2010-12-14 | 2016-10-04 | Rigshospitalet | radionuclide capture in nanoparticle compositions |
AR084366A1 (en) | 2010-12-20 | 2013-05-08 | Incyte Corp | N- (1- (REPLACED PHENYL) ETIL) -9H-PURIN-6-AMINAS AS PI3K INHIBITORS |
EP2672962B1 (en) | 2011-02-11 | 2015-03-25 | Moberg Pharma AB | Novel antifungal composition |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
DE102011106065A1 (en) * | 2011-06-13 | 2012-12-13 | Erlend Dinné | Pharmaceutical preparation |
HUE043703T2 (en) | 2011-09-02 | 2019-09-30 | Incyte Holdings Corp | Heterocyclylamines as pi3k inhibitors |
US20140343110A1 (en) | 2011-12-16 | 2014-11-20 | University Of Florida Research Foundation, Inc. | Uses of 4'-desferrithiocin analogs |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
GB201317619D0 (en) | 2013-10-04 | 2013-11-20 | Uni I Oslo | Compounds |
US20150141415A1 (en) * | 2013-11-20 | 2015-05-21 | Omonike Arike Olaleye | Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases |
US20170304288A1 (en) * | 2013-11-20 | 2017-10-26 | Texas Southern University | Formulations of Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
AU2015314287B2 (en) | 2014-09-12 | 2019-04-18 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
EP3198021B1 (en) | 2014-09-24 | 2020-12-16 | Colgate-Palmolive Company | Bioavailability of metal ions |
TWI764392B (en) | 2015-02-27 | 2022-05-11 | 美商英塞特公司 | Salts and processes of preparing a pi3k inhibitor |
KR20170140306A (en) * | 2015-04-27 | 2017-12-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | Metabolically programmed metal chelating agents and uses thereof |
TWI609013B (en) * | 2015-05-07 | 2017-12-21 | 國立臺北科技大學 | Novel compounds used for treating cancer |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
FR3038983A1 (en) | 2015-07-13 | 2017-01-20 | Centre Nat De La Rech Scient (Cnrs) | COMPOUNDS INHIBITING PSEUDOMONAS AERUGINOSA |
GB201613946D0 (en) | 2016-08-15 | 2016-09-28 | Univ Oslo | Compounds |
CZ309768B6 (en) * | 2017-06-05 | 2023-09-27 | Pharmacy point s.r.o | An antibacterial and antifungal hydrophilic gel composition based on a cross-linked copolymer of 2-hydroxyethyl methacrylate |
US11045589B2 (en) | 2017-09-22 | 2021-06-29 | Becton, Dickinson And Company | 4% trisodium citrate solution for use as a catheter lock solution |
JP2020536966A (en) * | 2017-10-13 | 2020-12-17 | ザ ユニバーシティー オブ クイーンズランド | Zinc ionophore and its use |
CN107988097A (en) * | 2017-11-29 | 2018-05-04 | 中国农业科学院油料作物研究所 | The flavobacterium breve biocontrol bacterial strain of one high-efficiency degradation aflatoxin and its application |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
CN111808090B (en) * | 2019-04-12 | 2023-05-02 | 中国医学科学院医药生物技术研究所 | New Deril metal-beta-lactamase-1 inhibitor |
WO2020242157A1 (en) * | 2019-05-31 | 2020-12-03 | 건국대학교 글로컬산학협력단 | Use of iox1 as antibiotic, anti-inflammatory, and anti-septic agent |
US11806342B2 (en) * | 2019-10-07 | 2023-11-07 | Purdue Research Foundation | Diiodohydroxyquinoline for the treatment of clostridium difficile infection |
CN111233850B (en) * | 2020-01-21 | 2022-09-23 | 南开大学 | Naphthol derivative containing benzothiazole amino and heteroaryl and preparation method and application thereof |
CN111514142B (en) * | 2020-05-29 | 2021-04-06 | 江苏亚虹医药科技股份有限公司 | Pharmaceutical composition containing nitroxoline prodrug and preparation method and application thereof |
EP4196154A1 (en) * | 2020-08-13 | 2023-06-21 | Texas Southern University | Compositions for and methods of inhibiting sars-cov2 infection |
JP2024509256A (en) * | 2021-03-09 | 2024-02-29 | ジュリス ゲルマナス, | Hydroxyquinoline compounds and their use as dye modifiers |
US20220401432A1 (en) * | 2021-05-27 | 2022-12-22 | Yuk Yin Sham | Therapeutic methods, combinations and kits |
WO2023212291A1 (en) * | 2022-04-29 | 2023-11-02 | Virginia Tech Intellectual Properties, Inc. | Treatment of pathogenic neisseria sp. infection with triazole antifungal agents |
CN115650912A (en) * | 2022-12-14 | 2023-01-31 | 灌南森迪门业有限公司 | 2-mercapto-6-methoxyquinoline-3-formaldehyde-N-oxide and synthesis method and application thereof |
-
2009
- 2009-05-11 WO PCT/US2009/043505 patent/WO2009140215A2/en active Application Filing
Non-Patent Citations (4)
Title |
---|
BERGERON RJ ET AL.: "Bacteriostatic and fungostatic action of catecholamide iron chelators.", ANTIMICROB AGENTS CHEMOTHER., vol. 24, no. 5, November 1983 (1983-11-01), pages 725 - 730 * |
CHEW BP ET AL.: "In vitro growth inhibition of mastitis causing bacteria by phenolics and metal chelators.", J DAIRY SCI., vol. 68, no. 11, November 1985 (1985-11-01), pages 3037 - 3046 * |
METT H ET AL.: "Duodeno-pancreatic secretions enhance bactericidal activity of antimicrobial drugs.", ANTIMICROB AGENTS CHEMOTHER., vol. 26, no. 1, July 1984 (1984-07-01), pages 35 - 38 * |
MURUGASU-OEI B ET AL.: "In vitro activity of the chelating agents nitroxoline and oxine against Mycobacterium bovis BCG.", INT J ANTIMICROB AGENTS., vol. 18, no. 6, December 2001 (2001-12-01), pages 579 - 582 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107847507A (en) * | 2015-05-29 | 2018-03-27 | 德克抗生素股份公司 | For treating the halo salicylanilide of fusobacterium infection |
Also Published As
Publication number | Publication date |
---|---|
WO2009140215A2 (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009140215A3 (en) | Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds | |
Cascioferro et al. | Therapeutic strategies to counteract antibiotic resistance in MRSA biofilm‐associated infections | |
CR20200148A (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
WO2008041966A3 (en) | Broad spectrum antibacterial compounds | |
WO2012034077A3 (en) | Compositions and methods related to attenuated staphylococcal strains | |
BR0317564A (en) | Compounds, compositions and methods for treating bacterial or fungal diseases | |
WO2009088549A3 (en) | Methods of inhibiting bacterial virulence and compounds relating thereto | |
WO2015100331A3 (en) | Phenazine derivatives as antimicrobial agents | |
WO2007021721A3 (en) | Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas | |
WO2008011164A3 (en) | Methods and compositions for the treatment and prevention of infections | |
WO2010115184A3 (en) | Hydroxythienoquinolones and related compounds as anti-infective agents | |
MX2021002719A (en) | Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains. | |
BRPI1010948A2 (en) | COMPOSITION UNDERSTANDING AT LEAST TRANS-CINAMALDEHYDE AND THEIR RESPECTIVE USE IN THE TREATMENT OF BACTERIAL INFECTIONS, MORE PARTICULARLY IN THE TREATMENT OF NOSOCOMIAL DISEASES. | |
WO2007133712A3 (en) | Antimicrobial therapy for bacterial infections | |
WO2020201833A8 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
EP4272831A3 (en) | Diazabicyclooctanones as inhibitors of serine beta-lactamases | |
WO2008036761A8 (en) | Anti-microbial defensin-related peptides and methods of use | |
RU2015134149A (en) | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS | |
WO2013041663A3 (en) | Modified apidaecin derivatives as antibiotic peptides | |
NZ706734A (en) | Pharmaceutical compositions useful for the treatment or control of bacterial infections | |
WO2010123599A3 (en) | Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus | |
WO2009013480A8 (en) | Antibacterial combination therapy | |
WO2015100448A3 (en) | Multimodal antimicrobial therapy | |
WO2011019736A3 (en) | System and method for controlling bacterial persister cells with weak electric currents | |
WO2017011730A3 (en) | Phenazine derivatives as antimicrobial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09747299 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09747299 Country of ref document: EP Kind code of ref document: A2 |